uniQure NV

QURENASDAQ · USD
37.82USD-0.41 (-1.08%)
1210

uniQure NV (QURE) Option Chain

As of September 25, 2026, uniQure NV is trading at $37.82, a -1.08% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 147.1%. IV Rank is 72%.

Read more

Tracking the QURE option chain helps you see every strike and expiry on uniQure NV in one view, so you can quickly identify the contracts that fit your thesis and your risk. uniQure NV's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of QURE options activity at a glance. Use our scanner to monitor the QURE option chain in real time and filter for the QURE options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For QURE stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the QURE option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where QURE stock options are being actively traded and where they are not.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls uniQure NV's full chain across every expiry, highlights the most liquid strikes, and lets you screen QURE options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of QURE stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile92.46% Elevated
  • Market cap (M$)2,652
  • 52 weeks high-46.53%
  • 52 weeks low337.92%
  • Analyst recommendationStrong Buy
    1.23
  • Target price$68.00
    79.80% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-09
  • P/E—
  • Future P/E—
  • EPS (ttm)-4.05
  • EPS growth next 5 years38.76%

As of September 25, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
49.885904.931.825.508.0036.00-5.833.505.100.004.30827250.12
53.0018305.330.825.107.2037.00-3.224.005.300.004.6521,13447.00
56.016712275.550.004.906.2038.00-0.604.505.600.184.87725843.99
58.927005.300.004.905.7039.00+2.014.906.301.184.4208041.08
61.712,0756065.200.004.905.5040.00+4.635.606.902.184.072453,14338.29

As of September 25, 2026

Scan the full option chain in one place

Browse the full QURE option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial